Ipca Laboratories Ltd plans to sell its Ankleshwar drug intermediates and APIs manufacturing unit to Suleshvari Pharma Pvt. Ltd. for Rs. 22.15 crores, with an expected completion date by December 31, 2025. The unit contributed Rs. 50.24 crores to revenue last year, which is only 0.74% of the total income.